Some clinical trials experts are concerned that statinassociated muscle symptoms (SAMS) are given more attention than the life-saving ability of these drugs, 1 and some experts doubt the existence of SAMS. 2 We recently completed a six-month, randomized-assignment, double-blind study of the effects of atorvastatin (80 mg daily) vs placebo on skeletal muscle performance, myalgia, and creatine kinase (CK) levels in 419 healthy adults. 3 There were no differences in muscle strength or exercise performance between the patient groups. More patients in the statin group (9.4%) met the study definition of myalgia vs placebo (4.6%) (p ¼ 0.054), and average CK increased 21 U/l (p < 0.001) with statin therapy. 3 We re-examined the data to determine how many statin-treated vs placebo-treated patients increased CK. CK increased from pretreatment values to six months more often in atorvastatin-treated (131 of 202, 64.9%) than in placebo-treated subjects (87 of 217, 40.1%) (p < 0.001). Also, 24 atorvastatin subjects increased their CK > 2 Â baseline levels compared to 12 placebo subjects (p ¼ 0.02). 4 Greater increases in CK with atorvastatin did not deleteriously impact skeletal muscle performance or predict myalgia. 4 The increase of CK in 65% of statin-treated subjects and the doubling of CK in 12% 4 suggests that statins produce mild muscle injury in a large proportion of treated patients. The long-term consequences of this observation are unknown.
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